On July 23, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to cobomarsen (MRG-106), for the treatment of T-cell lymphoma.
Cobomarsen is an inhibitor of microRNA-155 (miR-155). Overexpression of miR-155 is associated with poor prognosis in a variety of T-cell lymphomas and several other blood cancers. In 2017, the FDA and the European Medicines Agency (EMA) granted orphan drug designation to cobomarsen for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).
Cobomarsen is currently under investigation in two clinical trials, a phase II trial (NCT03837457) for CTCL and a phase I trial (NCT02580552) for adult T-cell leukemia/lymphoma (ATLL). It has demonstrated promising results in patients with CTCL and ATLL, and it could be potentially used as a broad-based therapy for the treatment of other cancers with elevated levels of miR-155.